Local hospital gets new technology to perform non-invasive surgery to remove liver cancer

A local hospital is using new technology to remove liver cancer without invasive surgery. It’s a word that no one ever wants ...
Nasdaq

Mainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert Project

Mainz Biomed N.V. has announced the next phase in its PancAlert project, which aims to develop a non-invasive blood test for early pancreatic cancer detection. Following a successful discovery ...
PharmiWeb

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
Science Daily

Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery

Pancreatic cysts are fluid-filled sacs that can form in the pancreas. Some remain benign, while others have the potential to develop into pancreatic cancer. A recent study, which followed 257 patients ...

Using AI to detect breast cancer in a safe and non-invasive manner

We combine affordable thermal cameras with advanced AI to analyse temperature maps of the human body without radiation, ...
Fred Hutch

Bladder Cancer Stages

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
Oncology Nurse Advisor

Less-Invasive Lymph Node Procedures Noninferior to ALND for Breast Cancer Recurrence

In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.
Morningstar

PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing ...

PEABODY, Mass., Nov. 17, 2025 /PRNewswire/ -- Privo Technologies today announced results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoengineered, cisplatin-releasing patch for ...